---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134765"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:07:04.195677+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sutro selects luvelta dose for registrational ovarian cancer trial; 32% ORR in Part 1

## Summary
- Selected dose: 5.2 mg/kg with prophylactic pegfilgrastim for 2 cycles then 4.3 mg/kg for subsequent cycles.
- Topline Part 1 (5.2 mg/kg, N=25): ORR 32%, DCR 96%; half of patients ineligible for approved FRα-targeting ADC.
- 88% of patients received prior bevacizumab; Grade 3+ neutropenia 32%, no febrile neutropenia.
- Part 2 registrational trial to enroll ~500 patients randomized 1:1 luvelta vs investigator's choice chemo.

## SEC filing metadata
- accession: 0000950170-24-134765
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017024134765/0000950170-24-134765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017024134765/stro-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134765
- JSON: https://secwatch.observer/filing/0000950170-24-134765.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.